INSP

SEC source: 0001104659-23-031810 · tm239130-3_4seq1.xml · nonDerivative · entry 5

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By GRAT

Disclosed balance after: 85,638

F5 · ownership.nature: Securities held by the Timothy P. Herbert 2018 Grantor Retained Annuity Trust.

SEC source: 0001104659-23-031810 · tm239130-3_4seq1.xml · nonDerivative · entry 4

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By GRAT

Disclosed balance after: 9,629

F1 · balance_after: The amount of securities listed in Column 5 reflects the total shares held following the transaction based on reference to the total reported in the Reporting Person's most recent Form 4, filed with the Securities and Exchange Commission ("SEC") on February 14, 2023.

F7 · ownership.nature: Securities held by the Timothy P. Herbert 2020 Grantor Retained Annuity Trust.

SEC source: 0001104659-23-031810 · tm239130-3_4seq1.xml · nonDerivative · entry 3

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,402

F1 · balance_after: The amount of securities listed in Column 5 reflects the total shares held following the transaction based on reference to the total reported in the Reporting Person's most recent Form 4, filed with the Securities and Exchange Commission ("SEC") on February 14, 2023.

F6 · balance_after: The Reporting Person's prior Form 4, dated February 14, 2023, understated the number of shares held directly by the Reporting Person by 3 shares of the Issuer's common stock.

SEC source: 0000947871-20-000208 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP V LLC · CIK 0001615374 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 347,000

F1 · price: These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $83.52.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong ("Khuong"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000209 · ownership.xml · nonDerivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 347,000

F1 · price: These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $83.52.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors.

F3 · ownership.nature: Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000193 · ownership.xml · nonDerivative · entry 3

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 847,000

F5 · price: These shares of the Issuer's common stock were sold in a block order at a price of $84.42.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors.

F3 · ownership.nature: Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000193 · ownership.xml · nonDerivative · entry 2

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,247,000

F4 · price: These shares of the Issuer's common stock were sold in a block order at a price of $84.55.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors.

F3 · ownership.nature: Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001104659-20-030294 · a4.xml · derivative · entry 11

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,187

Underlying: Common Stock · 10,000 shares

Expires 2023-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

F10 · derivative.expiration_date: This option grant was previously reported as having an expiration date of September 11, 2023, which has been revised herein.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 7

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.12. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 6

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.02 to $88.80. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 5

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,183

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.98 to $87.95. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 4

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,913

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.94 to $86.73. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 3

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,526

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.91 to $85.43. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 2

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,199

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.88 to $84.77. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-030294 · a4.xml · nonDerivative · entry 1

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000947871-20-000192 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP V LLC · CIK 0001615374 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 847,000

F5 · price: These shares of the Issuer's common stock were sold in a block order at a price of $84.42.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong ("Khuong"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000192 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP V LLC · CIK 0001615374 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,247,000

F4 · price: These shares of the Issuer's common stock were sold in a block order at a price of $84.55.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong ("Khuong"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000192 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP V LLC · CIK 0001615374 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,272,000

F1 · price: These shares of the Issuer's common stock were sold in a block order at a price of $83.21.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong ("Khuong"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-20-000193 · ownership.xml · nonDerivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,272,000

F1 · price: These shares of the Issuer's common stock were sold in a block order at a price of $83.21.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors.

F3 · ownership.nature: Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 6

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,469

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.08 to $88.45. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 5

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,769

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.00 to $87.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 4

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,069

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 3

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,169

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 2

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,625

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-028550 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,957

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.99. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-012076 · a4.xml · derivative · entry 12

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,187

Underlying: Common Stock · 10,000 shares

Expires 2023-09-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001104659-20-012076 · a4.xml · nonDerivative · entry 11

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.82 to $78.17. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-012076 · a4.xml · nonDerivative · entry 10

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 645

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.82 to $77.77. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-012076 · a4.xml · nonDerivative · entry 9

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,203

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.29 to $76.23. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-012076 · a4.xml · nonDerivative · entry 8

Ban Randy · CIK 0001737127 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-006316 · a4.xml · nonDerivative · entry 4

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,800

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.23. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-006316 · a4.xml · nonDerivative · entry 3

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001104659-20-006316 · a4.xml · nonDerivative · entry 2

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,212

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.14 to $83.11. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-006316 · a4.xml · nonDerivative · entry 1

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,812

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.09 to $82.03. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-004349 · a4.xml · nonDerivative · entry 5

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 15,324

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F1 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-20-004349 · a4.xml · nonDerivative · entry 4

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 30,492

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F1 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-20-004349 · a4.xml · nonDerivative · entry 3

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 30,567

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.92. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-20-003911 · a4.xml · nonDerivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,473

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

F2 · balance_after: Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V").

SEC source: 0001104659-20-003912 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,469

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

SEC source: 0001104659-20-003916 · a4.xml · nonDerivative · entry 1

NELSON MARILYN C · CIK 0001199894 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,489

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

SEC source: 0001104659-20-003915 · a4.xml · nonDerivative · entry 1

Ellis Gary Lee · CIK 0001290170 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,170

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

SEC source: 0001104659-20-003913 · a4.xml · nonDerivative · entry 1

Jain Mudit K. · CIK 0001584404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 975

F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

SEC source: 0001104659-20-002330 · a4.xml · nonDerivative · entry 2

Jain Mudit K. · CIK 0001584404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 820

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 7

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.41 to $76.33. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 6

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,512

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.38 to $75.27. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 5

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.29 to $76.07. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 4

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,612

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.22 to $75.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 3

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,672

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.18 to $74.12. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 2

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,812

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.15 to $73.015. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-20-002288 · a4.xml · nonDerivative · entry 1

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,006

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.11 to $72.06. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.